First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41308086.
- Also identified by DOI 10.1097/RLU.0000000000006201.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 78-year-old man with neuroendocrine neoplasm (NEN) G2 originating from a presacral tailgut cyst was previously treated with surgery, lanreotide and [ 177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT). Due to recurrence, confirmed by [ 68 Ga]Ga-DOTA-LM3 PET/CT, which showed local, hepatic, lymph nodal, soft tissue, and cardiac disease, he received 1 cycle of PRRT with somatostatin receptor (SSTR)-antagonist DOTA-LM3 labeled with alpha-emitting Actinium-225. Due to rising levels of bilirubin 2 months after therapy, an endoscopic retrograde cholangiopancreatography diagnosed bile duct stenosis and gastric adenocarcinoma (cause of death). Autopsy findings did not reveal any residual NEN, indicating complete remission after one cycle of alpha-PRRT.
Medical subject headings
- Neuroendocrine Tumors
- Cysts
- Receptors, Peptide